Search

Atomoxetine hydrochloride (generic) — Strattera (brand) [ABSTRACT FROM AUTHOR]

Attention‐deficit hyperactivity disorder, also known as ADHD, is a condition that often begins between ages 3 and 6, according to the National Institute of Mental Health. And it's not just a childhood disease. ADHD may continue through the teenage years and into adulthood. [ABSTRACT FROM AUTHOR]

Atomoxetine hydrochloride (generic) – Strattera (brand) [ABSTRACT FROM AUTHOR]

A meta‐analysis has found that selective serotonin reuptake inhibitors (SSRIs) are associated with a faster and better improvement than selective serotonin norepinephrine reuptake inhibitors (SSNRIs) in the treatment of generalized, separation, and/or social anxiety disorders in children. [ABSTRACT FROM AUTHOR]

The main predictor of a child with attention‐deficit/hyperactivity disorder (ADHD) being prescribed psychotropic medications in addition to stimulants is a psychiatric consultation, according to a new study from Canada. Researchers looked at children in Ontario to determine the predictors of medication prescription for ADHD in youth, as well as the prevalence and characteristics of youth with ADHD. [ABSTRACT FROM AUTHOR]

Legalization brings high-potency cannabis to market, with higher prices consumers are willing to pay, Stigma of medications may hinder treatment of opioid use disorders in adolescents, Atomoxetine 'sleep neutral' in children with ASD or ADHD, Vaping and marijuana top concerns in high school survey [ABSTRACT FROM AUTHOR]

Atomoxetine hydrochloride (generic) – Strattera (brand) [ABSTRACT FROM AUTHOR]

Children with autism spectrum disorder (ASD) who also have attention‐deficit hyperactivity disorder (ADHD) are also likely to have noncompliance — ignoring, refusing, defying, or arguing. Stimulants, while they work well for typically developing children with ADHD, have lower response rates in children with ASD. [ABSTRACT FROM AUTHOR]

The article focuses on atomoxetine hydrochloride. Topics discussed include the use of atomoxetine for the treatment of attention-deficit hyperactivity disorder (ADHD), risks related to atomoxetine such as emergence of suicidal ideation, severe liver injury and narrow angle glaucoma; and dosage instructions for children and adolescents.

The article reports on the findings of the study "Does atomoxetine improve executive function, inhibitory control, and hyperactivity? Results from a placebo-controlled trial using quantitative measurement technology," by P. M. Wehmeier and colleagues. It shows that children with attention-deficit hyperactivity disorder (ADHD) who received atomoxetine found to have improved the symptom. It indicates that atomoxetine had a significant effect on inhibitory control, hyperactivity, and function.

The article offers information on a research study by Samuel H. Zuvekas and colleagues that showed the stimulant use of attention-deficit/hyperactivity disorder (ADHD) in the adolescent age group. Researchers used the Medical Expenditure Panel Survey (MEPS) for examining the data for the 1996-2008 period. Results showed increased use of stimulant in the 13-to-18 age group at an annual rate of 6.5 percent from 1996-2008.

The article presents a study investigating the use of the medication atomoxetine for the treatment of attention-deficit/hyperactivity disorder (ADHD) in children of 5-to-6 age group. It is mentioned that behavioral treatments in addition to medication are critically important in the children of this age group.

The article offers information on atomoxetine hydrochloride. Topics discussed here include emergence of suicidal ideation, patients with bipolar disorder, and severe liver injury. Also being discussed are the topics like manic symptoms and hallucinations, narrow angle glaucoma, and slowing of growth.

The article presents questions and answers related to the drug atomoxetine hydrochloride (Brand: Strattera) including its uses, the risks in using the drug, and its side effects.

Few adverse events in RCT of atomoxetine in treatment of ADHD symptoms in children with ASD, AACAP expresses concern about AHCA, Bupropion may have benefits for ADHD [ABSTRACT FROM AUTHOR]

The article presents information on Atomoxetine hydrochloride (AH), a class of medications called selective norepinephrine reuptake inhibitor (SNRI). Topics covered include the use of AH for treating children and adults with attention-deficit hyperactivity disorder (ADHD) and risks such as manic symptoms, blood pressure changes and narrow angle glaucoma. Also mentioned are AH interactions with foods and other drugs, dosage, and other side effects.

The article presents a patient information sheet providing information on atomoxetine hydrochloride (brand: Strattera), including its use, risks, and side effects. It mentions that atomoxetine is used to treat attention-deficit hyperactivity disorder (ADHD) in children, adolescents and adults, with risks including increased suicidal ideation, patient with bipolar disorder, and sudden death. Also discussed are drug and food interactions, dosage, and storage.

The article offers information about atomoxetine, a class of medications called selective norepinephrine reuptake inhibitors (SNRIs). It is used for the treatment of attention-deficit hyperactivity disorder (ADHD) in children, adolescents, and adults. Atomoxetine may be associated with changes in pulse and blood pressure in some patients.

The article presents a meta-analysis aimed at assessing the consistency of the therapeutic efficiency of atomoxetine for treatment of attention-deficit hyperactivity disorder (ADHD) across Asia, Europe, North America, and Russia. It states that the therapeutic effects of atomoxetine demonstrated marginal inconsistency and moderate heterogeneity among ADHD patients in the four regions. The study showed a degree of heterogeneity in treatment efficiency across the four regions.

The article discusses research which examined abuse potential of nonstimulant drug atomoxetine, conducted by H. P. Upadhyaya and colleagues, published in a 2013 issue of "Psychopharmacology (Berl)" journal.

The November 2, 2012 patient information guideline for the use of the psychotropic drug Atomoxetine hydrochloride under the Strattera brand by Lilly USA LLC is presented. It provides an overview of the description of the drug, its use for the treatment of attention-deficit hyperactivity disorder (ADHD) in children and adults, and its adverse side effects and risks. It also outlines the potential drug interactions with other drugs and food, dosage forms, recommended dosage, and storage.

The article reports on the findings of the study "Age-specific prevalence, incidence of new diagnoses, and drug treatment of attention-deficit/hyperactivity disorder in Germany," by C. Lindemann and colleagues. It reveals an attention-deficit hyperactivity disorder (ADHD) prevalence rate of 2.5% in patients aged 3 to 17 years old, with four times higher in boys. It indicates that only 37% of them received a prescription for methylphenidate or atomoxetine drugs within a year of diagnosis.

The article offers information on a study which revealed that atomoxetine helps in reducing pervasive developmental disorders (PDDs) and attention-deficit/hyperactivity disorder (ADHD).

The article reports that the American Academy of Pediatrics (AAP) updated the guidelines for diagnosing, evaluating, and treating of the attention-deficit/hyperactivity disorder (ADHD) in children. It mentions that the ADHD evaluation includes an evaluation of emotional or behavioral comorbidites, oppositional defiant disorder (ODD) and conduct disorder (CD).

NIH teen brain study begins recruitment, Atomoxetine improves reading skills in children with dyslexia, Reduced IQ, polygenic risk scores for psychosis linked [ABSTRACT FROM AUTHOR]

Chart review finds atomoxetine safe and effective for ADHD symptoms and social withdrawal of ASD/ID, 1 in 6 children with ASD prescribed antipsychotics, Anxiety-BD link found [ABSTRACT FROM AUTHOR]

The article reports on the results of a new study which compares the neurofunctional modulation and normalization effects of acute doses of methylphenidate (MPH) and atomoxetine (ATX) in medication naive boys with attention-deficit hyperactivity disorder (ADHD) during working memory (WM) tasks.

The article offers information on the animal study which shows that methylphenidate (MPH) or atomoxetine could not address the deficiency of teenagers with attention-deficit hyperactivity disorder(ADHD) on set shift tasks.

The article discusses the once a day use of non-stimulants guanfacine extended-release (GXR) and atomoxetine (ATX) for the treatment of children and adolescents with attention-deficit hyperactivity disorder (ADHD).

The article reports on a study regarding the effect of atomoxetine in improving school function, attention, and visual memory of boys with attention deficit hyperactivity disorder (ADHD) in Taiwan.

The article reports on the study which compares the changes in brain activation relative to symptomatic improvements in attention-deficit hyperactivity disorder (ADHD) using stimulant methylphenidate hydrochloride compared to non-stimulant atomoxetine hydrochloride.

The article reports on the findings of the study "Common and unique therapeutic mechanisms of stimulant and nonstimulant treatments for attention-deficit/hyperactivity disorder," by K. P. Schulz and colleagues. It reveals that stimulant drug methylphenidate and non-stimulant atomoxetine for attention-deficit hyperactivity disorder (ADHD) treatment showed significant effect on neurophysiologic actions. It indicates improvements in response inhibition on tasks with both medications.

The article discusses the possibility of the combination of atomoxetine (ATMX) and stimulants for the treatment of attention-deficit hyperactivity disorder (ADHD) in the U.S. It provides an overview of the clinical use data regarding the ATMX-stimulants combination treatment, its prescriptions, and its efficacy and safety. It also looks into the positive results and adverse effects associated with combination treatment, along with the outcome differences based on age groups.

The article focuses on the treatment of attention-deficit hyperactivity disorder (ADHD) in young people having autism with atomoxetine which revealed no side-effects and moderate improvements.

The article focuses on a study which examines the efficacy of atomoxetine for treating comorbid autism spectrum disorder (ASD) and attention-deficit hyperactivity disorder (ADHD) in both of adult and young patients. The study suggests that presynaptic norepinephrine reuptake can be inhibited by atomoxetine, whose half-life is said to be longer than methylphenidate. It also claims that the administration of atomoxetine is effective in high-functioning autism and Asperger's Disorder patients.

The article presents a study which states that patients with attention-deficit hyperactivity disorder (ADHD) and intelligent quotients (IQ) less than 85, are less likely to respond to atomoxetine.

The article presents several case studies of patients with enuresis and attention-deficit/hyperactivity disorder (ADHD), which includes a nine-year-old girl, an 11-year-old boy and a 15-year-old boy. As mentioned, resolution of both enuresis and ADHD after children were treated with stimulant medication, were not identified.